| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
39,300,000 |
| Market
Cap: |
39.30(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6706 - $5.01 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CohBar is a clinical stage biotechnology company utilizing the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases with limited to no treatment options. In addition, Co. has multiple preclinical programs, such as a program in acute respiratory distress syndrome as well as earlier stage discovery programs. Co.'s pipelines include: CB5138-3, which is for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases; CB4211, which is for the treatment of nonalcoholic steatohepatitis and obesity; and CB5064 Analogs, family of peptides that are agonists of the apelin receptor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sarret Joseph J. |
Chief Executive Officer |
• • – |
2022-08-01 |
4 |
A |
$0.15 |
$19,495 |
D/D |
131,017 |
151,017 |
|
- |
|
| Biunno Jeffrey Francis |
CFO, Treasurer and Secretary |
• – – |
2022-08-01 |
4 |
A |
$0.15 |
$3,899 |
D/D |
26,203 |
57,355 |
|
- |
|
| Barzilai Nir Yacov |
Director |
– • – |
2021-11-01 |
4 |
B |
$0.00 |
$0 |
D/D |
13,889 |
5,075,405 |
2.31 |
-62% |
|
| Greenwood David |
Director |
– • – |
2021-11-01 |
4 |
B |
$0.00 |
$0 |
D/D |
20,000 |
40,000 |
2.31 |
-62% |
|
| Sarret Joseph J. |
Chief Executive Officer |
• • – |
2021-08-18 |
4 |
B |
$1.12 |
$22,400 |
D/D |
20,000 |
20,000 |
2.81 |
-70% |
|
| Biunno Jeffrey Francis |
CFO, Treasurer and Secretary |
• – – |
2021-08-18 |
4 |
GA |
$0.00 |
$0 |
I/I |
4,000 |
5,000 |
|
- |
|
| Biunno Jeffrey Francis |
CFO, Treasurer and Secretary |
• – – |
2021-08-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,000 |
31,152 |
|
- |
|
| Cundy Kenneth C |
Chief Scientific Officer |
• – – |
2021-08-11 |
4 |
AS |
$2.01 |
$20,100 |
D/D |
(10,000) |
10,000 |
|
-75% |
|
| Cundy Kenneth C |
Chief Scientific Officer |
• – – |
2021-08-11 |
4 |
OE |
$0.73 |
$7,300 |
D/D |
10,000 |
20,000 |
|
- |
|
| Cundy Kenneth C |
Chief Scientific Officer |
• – – |
2021-02-16 |
4 |
AS |
$1.90 |
$19,000 |
D/D |
(10,000) |
10,000 |
|
-34% |
|
| Cundy Kenneth C |
Chief Scientific Officer |
• – – |
2021-02-16 |
4 |
OE |
$0.73 |
$7,300 |
D/D |
10,000 |
20,000 |
|
- |
|
| Biunno Jeffrey Francis |
CFO, Treasurer and Secretary |
• – – |
2020-12-18 |
4 |
B |
$0.00 |
$0 |
D/D |
7,490 |
17,490 |
2.66 |
-5% |
|
| Stern Jon Leland |
Director |
– • – |
2020-12-18 |
4 |
B |
$0.00 |
$0 |
D/D |
99,861 |
674,012 |
2.31 |
-5% |
|
| Petkevich Misha |
Director |
– • – |
2020-09-03 |
4 |
B |
$1.02 |
$11,220 |
I/I |
11,000 |
240,609 |
2.1 |
40% |
|
| Petkevich Misha |
Director |
– • – |
2020-09-02 |
4 |
B |
$1.00 |
$6,000 |
I/I |
6,000 |
229,609 |
2.1 |
28% |
|
| Greenwood David |
Director |
– • – |
2020-08-28 |
4 |
B |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
2.31 |
53% |
|
| Fitzgerald Albion |
Director |
– • – |
2020-08-28 |
4 |
B |
$0.00 |
$0 |
D/D |
8,196 |
937,863 |
2.31 |
53% |
|
| Petkevich Misha |
Director |
– • – |
2020-08-28 |
4 |
B |
$0.00 |
$0 |
I/I |
204,918 |
223,609 |
2.02 |
53% |
|
| Stern Jon Leland |
Director |
– • – |
2020-08-28 |
4 |
B |
$0.00 |
$0 |
D/D |
8,169 |
574,151 |
2.31 |
53% |
|
| Cundy Kenneth C |
Chief Scientific Officer |
• – – |
2020-08-06 |
4 |
AS |
$1.90 |
$19,000 |
D/D |
(10,000) |
10,000 |
|
-26% |
|
| Cundy Kenneth C |
Chief Scientific Officer |
• – – |
2020-08-06 |
4 |
OE |
$0.73 |
$7,300 |
D/D |
10,000 |
20,000 |
|
- |
|
| Cundy Kenneth C |
Chief Scientific Officer |
• – – |
2020-06-15 |
4 |
AS |
$2.41 |
$24,100 |
D/D |
(10,000) |
10,000 |
|
-63% |
|
| Cundy Kenneth C |
Chief Scientific Officer |
• – – |
2020-06-15 |
4 |
OE |
$0.73 |
$7,300 |
D/D |
10,000 |
20,000 |
|
- |
|
| Cundy Kenneth C |
Chief Scientific Officer |
• – – |
2020-05-15 |
4 |
AS |
$2.56 |
$25,600 |
D/D |
(10,000) |
10,000 |
|
-63% |
|
| Cundy Kenneth C |
Chief Scientific Officer |
• – – |
2020-05-15 |
4 |
OE |
$0.73 |
$7,300 |
D/D |
10,000 |
20,000 |
|
- |
|
98 Records found
|
|
Page 1 of 4 |
|
|
